Epstein-Barr virus peptide-Human Leukocyte Antigen complex (EBNA1, LMP1, LMP2) (EBV peptide-HLA complex)

Epstein-Barr virus (EBV) peptide-HLA complexes are critical immunological targets formed by the presentation of viral fragments on the surface of infected cells. These complexes consist of specific peptides derived from EBV latent proteins—Epstein-Barr nuclear antigen 1 (EBNA1), Latent membrane protein 1 (LMP1), and Latent membrane protein 2 (LMP2)—bound to Human Leukocyte Antigen (HLA) molecules. EBNA1 is vital for the replication and maintenance of the episomal EBV genome, while LMP1 and LMP2 function as viral oncogenes that mimic CD40 and B-cell receptor signaling, respectively, to drive cellular proliferation and survival. In EBV-associated malignancies such as nasopharyngeal carcinoma and post-transplant lymphoproliferative disorder, these proteins are consistently expressed, making their peptide-HLA complexes ideal targets for T-cell-based therapies. Current therapeutic approaches involve the use of EBV-specific T-cells (VSTs) or engineered T-cell receptor (TCR) therapies designed to recognize these specific pMHC (peptide-MHC) signatures and induce apoptosis in the target cells. Tabelecleucel is a notable example of an allogeneic T-cell therapy targeting these complexes that has gained regulatory approval for specific EBV-related conditions.

Other names

EBV pMHCEBV-specific HLA-peptide complexEBNA1/LMP1/LMP2-HLA complexesEpstein-Barr virus antigen-MHC complex

T-cell receptor (TCR) mediated recognition leading to cytotoxic T-lymphocyte (CTL) activation and targeted lysis of EBV-infected or malignant cells.